A generics trade association believes the US can boost its drug manufacturing base if the government is willing to pay a premium for the essential medicines the new facilities would produce.
Pricing of the domestically-produced drugs may prove the most important and difficult hurdle if the Association for Accessible Medicines’ Blueprint for Enhancing the Security of the US Pharmaceutical Supply Chain is to be implemented
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?